Prospective study reveals improvement in ocular symptoms in patients with ocular graft-versus-host disease, indicating cyclosporine's benefits.
Key Points
Significant improvements in ocular symptoms and surface metrics observed at multiple time points, enhancing patient quality of life.
Patients treated with topical cyclosporine showed reduced corneal fluorescein staining, indicating better ocular surface health by the sixth month.
Ophthalmic exams showed no alterations in corneal sub-basal nerve morphology, underscoring the need for deeper investigation into nerve health.
While the treatment improved ocular surface disease metrics, it did not significantly affect corneal innervation, suggesting limited impact on nerve condition.